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Background The recent international GUSTO trial of
41 021 patients with acute myocardial infarction demon-
strated improved 90-min infarct related artery patency as
well as reduced mortality in patients treated with an accel-
erated regimen of tissue plasminogen activator, compared
to patients treated with streptokinase. A regimen combin-
ing tissue plasminogen activator and streptokinase yielded
intermediate results. The present study investigated the
effects of treatment on infarct size and enzyme release
kinetics in a subgroup of these patients.
Methods A total of 553 patients from 15 hospitals were
enrolled in the study. Four thrombolytic strategies were
compared: streptokinase with subcutaneous heparin, strep-
tokinase with intravenous (i.v.) heparin, tissue plasminogen
activator with i.v. heparin, and streptokinase plus tissue
plasminogen activator with i.v. heparin. The activity of
alpha-hydroxybutyrate dehydrogenase (HBDH) in plasma
was centrally analysed and infarct size was defined as
cumulative HBDH release per litre of plasma within 72 h of
the first symptoms (Q(72)). Patency of the infarct-related
vessel was determined by angiography in 159 patients,
90 min after treatment.
Results Infarct size was 3-72 g-eq. 1 - 1 in patients with
adequate coronary perfusion (TIMI-3) at the 90 min angi-
ogram and larger in patients with TIMI-2 (4-35 g-eq . 1 ')
or TIMI 0-1 (507 g-eq . 1" ') flow (P=0-024). In this subset
of the GUSTO angiographic study, early coronary patency
rates (TIMI 2 + 3) were similar in the two streptokinase
groups (53 and 46%). Higher, but similar, patency rates
were observed in the tissue plasminogen activator and
combination therapy groups (87 and 90%). Median infarct
size for the four treatment groups, expressed in gram-
equivalents (g-eq) of myocardium, was 4-4, 4-5, 3-9 and
3-9 g-eq per litre of plasma (P=0-04 for streptokinase vs
tissue plasminogen activator). Six hours after the first
symptoms, respectively 5-3, 6-6, 140 and 13-6% of total
HBDH release was complete (/><00001 for streptokinase
vs tissue plasminogen activator).
Conclusions Rapid and complete coronary reperfusion
salvages myocardial tissue, resulting in limitation of infarct
size and accelerated release of proteins from the myo-
cardium. Treatment with tissue plasminogen activator, re-
sulting in earlier reperfusion was more effective in reducing
infarct size than the streptokinase regimens, which con-
tributes to the differences in survival between treatment
groups in the GUSTO trial.
(Eur Heart J 1996; 17: 237-246)
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Introduction
Prognosis of patients with myocardial infarction is
markedly improved by timely reperfusion of the
ischaemic myocardium. The GUSTO trial recently dem-
onstrated differences in outcome from four treatment
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regimens1'1, which could be explained by different rates
of early coronary reperfusion, varying between 81% for
accelerated tissue plasminogen activator with i.v.
heparin and 54 and 60% for streptokinase with subcuta-
neous or intravenous heparin'21. Early reperfusion of the
ischaemic myocardium allows recovery and salvage of
myocytes and preserves left ventricular function'31. This
concept was confirmed by the angiographic study in
GUSTO, which demonstrated small but significant
improvements in regional and global left ventricular
function with the accelerated tissue plasminogen activa-
tor regimen'2'. Infarct size can be assessed from regional
left ventricular function, and measured directly by
assessing cumulative protein release from the infarcted
myocardium'4'51. The cumulative amount of myocardial
enzymes or other proteins that can be recovered from
plasma samples correlates closely with infarct size, as
determined by pathology examinations'6"91.
In the setting of thrombolytic therapy, the
pattern of protein release from the infarct changes. First,
proteins such as creatine kinase appear earlier after
symptom onset, reflecting either rapid washout or (more
likely) accelerated disruption of myocytes after coronary
reperfusion'101. Secondly, later release of proteins is
reduced after thrombolysis. Thus, in spite of an early
and often high peaking of creatine kinase and other
proteins after coronary reperfusion, the total amount of
proteins released from the infarcted tissue is reduced
by thrombolytic therapy. Limitation of infarct size by
different regimens of thrombolytic therapy ranged from
20% to 35% when compared with conventional
therapy1"1 or placebo1'21.
Within the GUSTO trial, a substudy was con-
ducted to assess the patterns of enzyme release in the
four treatment groups. In particular, this substudy was
designed to verify the relationships among early cor-
onary patency, infarct size, left ventricular function and
survival. A priori it was postulated that more rapid
reperfusion in patients receiving tissue plasminogen
activator (either the accelerated regimen or in combi-
nation with streptokinase) would result in smaller infarct
size when compared with the streptokinase regimens.
Methods
Patients and thrombolytic strategies
Additional data for the enzyme substudy were collected
from 553 GUSTO patients enrolled in 15 hospitals in
four European countries. Inclusion criteria have been
described in detail'11. In short, patients with onset of
symptoms less than 6 h before enrolment, chest pain
lasting at least 20 min and ST segment elevation
^ 0 1 mV in two or more limb leads, or ^>0-2 mV in two
or more precordial leads were eligible. Patients with a
history of stroke, recent trauma or major surgery, active
bleeding or previous treatment with streptokinase or
anistreplase were excluded. After informed consent,
patients were randomized to one of four intravenous
thrombolytic regimens: (1) streptokinase, 15 million U
in 60 min, with subcutaneous heparin, 12 500 U twice
daily, beginning 4 h after the start of thrombolytic
therapy until day 7 or hospital discharge; (2) strepto-
kinase 1-5 million U in 60 min, with intravenous heparin
in a bolus dose of 5000 U followed by 1000 U per hour
for at least 48 h, with the dose adjusted to prolong the
activated partial thromboplastin time to 2—2-5 times
normal; (3) accelerated alteplase, bolus of 15 mg, fol-
lowed by 0-75mg.kg"' (not to exceed 50 mg) over
30 min and 05 mg . kg~ ' (not to exceed 35 mg) over the
next 60 min, along with intravenous heparin; (4) the
combination of alteplase (10 mg . kg" ', not to exceed
90 mg, over 60 min with 10% given as an initial bolus)
and streptokinase (10 million U over 60 min), along
with intravenous heparin. All patients received aspirin.
Patients without contraindication to beta-blockade
received intravenous atenolol ( 2 x 5 mg), followed by 50
to 100 mg orally per day. All other medication was left
to the discretion of the attending physician.
Angiographic substudy
In 10 out of the 15 participating hospitals, patients were
also enrolled in the Angiographic Substudy*21 and were
randomly assigned to angiography at 90 min, 180 min,
24 h or 5-7 days after the start of thrombolysis. Patients
randomized to angiography at 90 min were also assigned
to follow-up angiography 5-7 days later. The infarct-
related artery was identified by ECG and angiographic
data combined. The first injection into this artery was
used to determine coronary perfusion according to
TIMI criteria'13': no flow (grade 0), minimal filling
(grade 1), incomplete or delayed filling (grade 2) and
normal flow (grade 3). Global left ventricular function
and regional wall motion were measured'2'.
Collection of plasma samples and enzyme
determination
Participating hospitals received instructions on blood
collection and sample handling. Twelve out of the 15
participating hospitals obtained 11 blood samples at 0,
1, 3, 6, 12, 18, 24, 36, 48, 72 and 96 h after the start of
thrombolytic therapy. The first six samples were drawn
within 30 min of the intended time, later samples could
be synchronized to routine phlebotomy. Three hospitals
(not participating in the Angiographic Substudy) were
not able to adhere to this frequent sampling schedule
and collected five samples: at enrolment and between
0800 and lOOOh on the following 4 days. In all cases, the
exact time of sampling was recorded in the GUSTO
Enzyme Case Report Form. Venous blood samples of
5-10 ml were collected in predistributed tubes contain-
ing dry heparin to prevent clotting. Blood samples from
indwelling catheters were allowed provided that the first
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few drops were discarded to prevent dilution with infu-
sion fluids. After centrifugation for 10-15 min at 1000-
2000 x g, the supernatant plasma was collected and
stored at - 20 °C, leaving some plasma on the sediment
to prevent contamination by blood cells.
Within 8 weeks, plasma samples were trans-
ported in polystyrene boxes with dry ice to the Enzyme
Core Laboratory at Maastricht, The Netherlands, for
central analysis. Haemolytic samples, as detected by
visual inspection, and those arriving thawed were
discarded. The remaining were stored at — 80 °C.
Plasma activity of alpha-hydroxybutyrate dehydroge-
nase (HBDH) was determined by spectrophotometry,
using a centrifugal analyser (Cobas Bio System,
Hoffmann la Roche, Basle, Switzerland) and a commer-
cial test kit (Boehringer Mannheim, Germany). The
HBDH test mainly measures the myocardial isoforms
LDH1 and LDH2 of lactate dehydrogenase (EC
1.1.1.27), by means of their higher catalytic activities in
the conversion of alpha-ketobutyrate. Determinations
were performed in duplicate at 25 °C, within 6 weeks
after arrival of the samples in Maastricht. Activities were
expressed in micromoles of substrate converted per
minute per litre of plasma [U . P '].
Determination of infarct size
Cumulative release of HBDH activity per litre of plasma
between the onset of symptoms (t = 0) and time t,
indicated as Q(t), was calculated as described'4'5' from
the expression:
Q(t) = C(t) + TER }< C(T)dT+FCR r C(T)dTtr
with C(t) the plasma activity of HBDH, TER the
fractional transcapillary escape rate constant, ERR the
fractional extravascular return rate constant and FCR
the fractional catabolic rate constant for the elimina-
tion of HBDH activity from plasma. Values of C(t)
were obtained by subtraction of the normal steady-
state plasma activity C, from the actually measured
activities. If the first measurement of plasma HBDH
activity was performed within 3 h of the first symp-
toms, the obtained value was used for C5; otherwise a
fixed mean value of 82 U . 1 ~ ' was used. Values used
for TER, ERR and FCR were respectively 0014h" 1 ,
0018 h " 1 and 0-015 h"1'4-51. Infarct size was defined
as Q(t) calculated over 72 h, that is Q(72). Q(72) was
divided by the normal HBDH content of human myo-
cardium determined with the same assay, that is, 123 U
per gram of wet weight'14'151 to obtain infarct size in
gram-equivalents of myocardium per litre of plasma
(g-eq. I"1).
To assess differences in release pattern, the
proportion of early HBDH release in the first 6 or 12 h
was calculated as Q(6)/Q(72) and Q(12)/Q72.
Statistical analysis
Results were analysed on an intention-to-treat basis with
imputation for missing data. To this end, a value of
11 0 g-eq . 1 ~ ' for Q(72) was allotted to patients who
died early, and a value of 4-9 g-eq . 1~' to 39 remaining
cases with missing data. The first value was the mean
infarct size found in six patients who died within 4 days
after the first symptoms, and the second value was the
overall mean infarct size in the 502 cases that allowed
calculation of infarct size. At the start of the Enzyme
Substudy it was appreciated that the sample size would
not allow detection of differences in infarct size among
all four GUSTO treatment groups. Therefore, it was
decided to combine the two tissue plasminogen activator
groups as well as the two streptokinase regimens in the
primary analysis. Furthermore, the intention was to
enroll consecutive patients in order to avoid systematic
bias in subsequent comparisons of the enzyme results.
Data analysis was performed with standard soft-
ware packages (BMDP Statistical Software, Inc., Los
Angeles, version 1990 and SAS Institute Inc., Cary
release 6 08). Median values were calculated. The signifi-
cance of differences was tested two-tailed according to
Kruskal-Wallis or Mann-Whitney. Multiple linear re-
gression analysis was performed with BMDP routine
1R. Regression lines were computed in SAS.
Results
A total of 553 consecutive patients were enrolled into the
GUSTO Enzyme Substudy, of whom 502 patients had
enzyme data allowing calculation of Q(72). Twelve
patients died before Q(72) could be determined and 39
cases could not be analysed because of haemolytic
plasma samples, arrival of thawed plasma samples in
Maastricht, or administrative errors. Baseline character-
istics of the 553 patients did not differ from the 41 021
patients in the GUSTO main trial (Table 1). There were
also no significant differences in baseline characteristics
among the four treatment groups within the Enzyme
Substudy.
Coronary patency, infarct size and
enzyme release
Coronary angiography was performed in 159 patients
within 2 h of the start of treatment (Table 1). In this
subgroup of the GUSTO angiographic study, complete
perfusion (TIMI-3) was observed in similar proportions
of patients receiving accelerated alteplase as the combi-
nation regimen. As in the larger study, TIMI scores
were worse in patients treated with the streptokinase
regimens. A marked association between early TIMI
scores and infarct size was observed. Median infarct
size was 3-72 (25th and 75th percentile respectively 1 -43
and 6-48) g-eq . 1~' in patients with normal coronary
Eur Heart J, Vol. 17, February 1996
240 T. Baardman et al.
Table 1 Baseline data and selected outcome parameters
Baseline characteristics
Number of patients
Age (years)
Female sex (%)
Infarct location Anterior (%)
Inferior (%)
Other (%)
Previous infarction (%)
Previous coronary surgery (%)
Time to treatment (h)
Selected clinical events
24 h mortality (%)
30 day mortality (%)
All strokes (%)
Coronary angiography at 90 min
Number of patients
TIM I 3 (patients)
2
0-1
patent TIMI 3 (%)
TIMI 2 + 3 (%)
Main
trial
41 021
62
25
39
58
3
16
4
2-8
2-7
70
1-5
Enzyme
cohort
553
62 (54-69)
23
40
56
4
15
2
2-8 (20-3-8)
1-6
4-5
11
159
65
50
44
41
72
SK
s.c. hep.
139
61 (52-69)
21
40
56
4
17
3
2 8 (2-2-3-8)
1-4
2-9
0-7
40
7
14
19
18
53
SK
i.v. hep
136
63 (55-70)
28
36
60
4
10
4
2-6 (1-8-3-8)
2-9
81
1-5
26
7
5
14
27
46
tPA
i.v. hep.
137
62 (52-70)
22
43
54
4
19
2
2-8 (2 1-3-7)
0-7
2-9
0-7
52
29
16
7
56
87
tPA + SK
i.v. hep.
141
62 (55-69)
19
42
54
4
15
1
2-8 (2-0-3-8)
1-4
4-3
1-4
41
22
15
4
54
90
SK = streptokinase; s.c. hep = subcutaneous heparin; i.v. hep=intravenous heparin; tPA = alteplase. Values followed by numbers in
parentheses are medians, with the 25th and 75th percentiles shown inside the parentheses.
72
Figure 1 HBDH release patterns (Q) over 72 h for patients witb TIMI 3 ( • ,
n = 65), 2 (+, n = 50) or 0/1 (*, m=44) at the 90 min angiogram. *Indicates a
significant difference between the groups (y<0-05).
perfusion (TIMI-3), 4-35 (2-63, 640) g-eq . 1~' in
patients with incomplete perfusion (TIMI-2) and 5-07
(3-73, 8-22) g-eq . 1 ~ ' in those with minimal or no per-
fusion (TIMI-0,1) (Fig. 1). The differences among the
Eur Heart J, Vol. 17, February 1996
three groups were significant at 48 h (/>=0047) and at
72 h (/>=f>024).
The overall pattern of enzyme release varied
among the three patient groups. In patients with normal
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Figure 2 Percentage of Q72 released for patients with TIMI 3 ( • , n = 65), 2 ( + ,
n=41), and 0/1 (*, n=42) at the 90 min angiogram. Q72 denotes the cumulative
release of HBDH at 72 h. indicates a significant difference between the groups
Table 2 Effect of treatment on median infarct size (Q(72)) expressed in g-eq. I '
SK + s.c. hep SK+i.v. hep tPA + i.v. hep tPA + SK + i.v. hep SK combined tPA combined /"-value forSK vs tPA
n=125
4 36
2-5-6-7
With imputation
n=139
4-90
2-6-6-5
n=120
4-52
2-6-7-1
for missing cases (see
n=136
4-90
2-8-7-1
n=130
3-92
1-6-6-4
text):
n = 137
4-39
1-7-6-3
n=127
3-88
1-9-6-6
n=141
4-17
2-1-6-7
n = 245
4-39
2-5-6-8
n = 275
4-90
2-7-6-8
n = 257
3-88
1-7-6-6
n = 278
4-35
2-0-6-6
0043
0034
Abbreviations as in Table 1, n = number of patients. Medians with the 25th and 75th percentiles are given.
perfusion at early angiography a greater proportion was
released within the first 6 or 12 h (Fig. 2, P<, 0002).
Because the proportion of early HBDH release can be
meaningfully calculated only in patients with a complete
series of early samples, only 343 patients who had at
least 10 samples and Q(72) exceeding 0-5 g-eq . 1 ~ ' were
used for this analysis.
Effect of treatment on infarct size and
enzyme release kinetics
Table 2 presents the median values of Q(72) for the four
treatment groups, without and with imputation for
missing cases, and for the combined tissue plasminogen
activator and streptokinase groups. Patients treated with
accelerated tissue plasminogen activator or combination
therapy had infarcts that were 12% smaller then those
who received streptokinase therapy. These differences
were apparent, but not statistically significant in a
four-group comparison (Kruskal-Wallis, />=0-19).
However, the pooled patients receiving streptokinase
only differed significantly (,P=0043) from the patients
receiving either tissue plasminogen activator or tissue
plasminogen activator plus streptokinase. Because of the
high value of 110 g-eq . 1 ~ ' used for the patients who
died early (see Methods), imputation raised the median
values by 10-15%, but these trends remained un-
changed. Due to the higher number of deaths in the
streptokinase patients (see Table 1) imputation resulted
in a slightly more significant difference (P^O-034) be-
tween the combined tissue plasminogen activator and
the combined streptokinase groups.
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Table 3 Effect of treatment
0(3)
0(4)
0(6)
0(9)
Q(12)
Q(6VQ(72)
Q(12)/Q(72)
SK+s.c. hep 5
n = 87
0-00
001
015
0-74
1-29
0053
0-282
on early HBDH release expressed in g-eq. I '
>K + i.v. hep
n = 77
0-00
002
0-30
0-87
1-34
0066
0-318
tPA + i.v. hep
n=95
002
009
0-41
0-88
1 35
0140
0-372
tPA + SK + i.v. hep
n = 84
003
013
0 41
1-20
1 76
0136
0-423
JSL.
n=164
000
001
0-23
0-77
1-32
0062
0-295
tPA
n = 179
0-02
Oil
0-41
0-97
1 57
0140
0-319
/"-value for
SK. vs tPA
0-002
00001
00001
0-07
0-55
<00001
<0-001
Abbrevations as in Tables 1 and 2. Medians of cumulative HBDH release (Q) are given for the first 3, 4, 6, 9 and 12 h, and ratios of early
release are given (Q(6)/Q(72) and Q(12)/Q(72)).
12 24 38 48 60
1 -
72 0
Time(h)
12 38 48 60 72
Figure 3 HBDH release patterns (Q) of patients treated with streptokinase (X) (and intravenous or
subcutaneous heparin) or with alteplase ( • ) (and intravenous heparin or with streptokinase and intravenous
heparin). * indicates a significant difference between the groups (/><0-05). For comparison, data of the European
Cooperative Study Group (rt-PAVplacebo trial), are presented (right panel). Note accelerated (early) release
for tissue plasminogen activator ( • ) in comparison with both placebo ( x , right panel) as well as streptokinase
( x , left panel).
Early release of HBDH, expressed in g-eq .1 ',
within the first 12 h after onset of symptoms is presented
in Table 3 for 343 patients with at least 10 samples. In
spite of the larger ultimate infarct size in the strepto-
kinase groups (Table 2), release up to 6 h after first
symptoms was significantly lower in the combined strep-
tokinase groups, compared with the combined tissue
plasminogen activator groups. Differences between
ratios Q6/Q72 and Q12/Q72 were more significant than
differences between absolute values of Q6 and Q12
(Table 3). This reflects two distinct effects on release
kinetics: enhancement of early release and reduction of
late release in patients treated with tissue plasminogen
activator vs patients treated with streptokinase. This is
also illustrated in Fig. 3.
In order to verify whether the effect of treatment
could be caused by factors other than infarct-related
artery patency, multiple linear regression analysis was
performed using Q(72) as the dependent variable and
treatment (streptokinase vs tissue plasminogen activa-
tor) as well as TIMI score (3 vs 2 vs 0 or 1) as
independent variables. In this analysis, the contribution
of treatment became totally insignificant (P=0-97) while
the effect of TIMI score remained highly significant
(P<00l). This indicates that the effect of treatment
on infarct size may be explained by its effect on
90-min infarct-related artery patency. Similarly, multiple
linear regression analysis with Q(12)/Q(72) as the
dependent variable and treatment (streptokinase vs
tissue plasminogen activator) and TIMI score (3 vs 2 vs
0 or 1) as independent variables demonstrated that the
effect of treatment on the acceleration of enzyme release
was explained by early coronary patency.
Infarct size and left ventricular function
Both infarct size and left ventricular function measure-
ments at 5-7 days after allocation were available in 156
patients with a first myocardial infarction. There was an
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Figure 4 Left ventricular (LV) ejection fraction (LVEF) 5-7 days after a first myocardial
infarction against Q72. Q72 denotes the cumulative release of HBDH at 72 h. The linear
regression line for all patients is given in the figure. The regression lines for the four treatment
groups did not differ (intercept and slope for alteplase+intravenous heparin ( • ) were, respec-
tively, 70 and —1-9; for steptokinase+intravenous heparin (+) 72, —2-2; for alteplase+
streptokinase+intravenous heparin ( • ) 72, - 2 - 2 and for streptokinase and subcutaneous
heparin ( x ) 72, - 1-8).
inverse relationship between infarct size and both left
ventricular ejection fraction and regional wall motion of
the infarct zone. This relationship for left ventricular
ejection fraction is shown in Fig. 4. Regression lines
were computed as shown in Fig. 4, indicating consistent
relationships between infarct size and global or regional
left ventricular function, independent of the treatment
regimens.
Discussion
In GUSTO, treatment with accelerated tissue plasmino-
gen activator yielded improved survival compared with
two streptokinase regimens. The absolute difference in
30 day mortality was 1%, which corresponded to a 14%
relative mortality reduction1'1. Intermediate results were
obtained with the combined regimen of tissue plasmino-
gen activator with streptokinase. These differences could
be explained by more frequent early reperfusion in
patients receiving tissue plasminogen activator, as docu-
mented by the GUSTO angiographic substudy121. The
present GUSTO enzyme substudy extends these findings
and confirms the concept that the improved survival
after treatment with accelerated tissue plasminogen ac-
tivator in comparison with streptokinase11' is related to
myocardial salvage by more rapid coronary reperfusion.
Indeed, infarct size in patients treated with tissue plas-
minogen activator appeared to be 12% smaller than in
those receiving streptokinase.
It should be appreciated that the mortality and
patency results in this substudy are compatible with, but
not identical to, those in the larger trial (Table 4). In
particular, early coronary patency was almost identical
among patients receiving accelerated tissue plasminogen
activator or the combination regimen (tissue plasmino-
gen activator within streptokinase) in this subset of the
angiographic substudy. This is in agreement with the
infarct size measurements, which were almost identical
in these two groups. Accordingly, the predefined inten-
tion to compare the two tissue plasminogen activator
regimens (accelerated tissue plasminogen activator and
combined tissue plasminogen activator and strepto-
kinase) with the two streptokinase regimens appeared
justified. In contrast, in the larger angiographic substudy
and in the mortality study, both early patency and
survival for the combination regimen were intermediate
between the figures for accelerated tissue plasminogen
activator and the streptokinase groups, and combina-
tion of the two regimens containing tissue plasminogen
activator would not be appropriate.
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Table 4 Comparison
90 min patency (%)
Enzyme substudy
Angio substudy
30 day mortality (%)
Enzyme substudy
Angio substudy
GUSTO main trial
of outcomes in
TIMI 3
TIMI 2 + 3
TIMI 3
TIMI 2 + 3
different GUSTO
SK + s.c. hep
18
53
29
54
2-9
6-5
72
cohorts
SK + i.v. hep
27
46
32
60
81
75
74
tPA + i.v. hep
56
87
54
81
29
53
6-3
tPA + SK + i.v. hep
54
90
38
73
4-3
7-8
70
Abbreviations as in Table 1.
Estimation of infarct size in patients
receiving thrombolytic therapy
The validity of using myocardial enzyme release into
plasma for estimation of infarct size has been demon-
strated in several clinical studies16"91 and in experimental
studies on permanent coronary artery ligation in
dogs'16"18' using histological staining of the infarcted
area as the gold standard. These studies have shown
highly significant relationships between total infarcted
muscle volume and peak values or cumulative release of
enzymes such as creatine kinase, lactate dehydrogenase
and aspartate aminotransferase. In patients treated with
thrombolytic therapy, however, some clinical studies
have indicated altered relationships between the release
of creatine kinase, or creatine kinase-MB into plasma
and myocardial injury as estimated from an independent
parameter such as left ventricular ejection fraction1'9"2'1
or thallium-201 defect1221. In these studies, thrombolysis
caused extra release of creatine kinase, creatine kinase-
MB compared with control patients for the same degree
of damage as determined from the independent variable.
Reperfusion also resulted in enhanced creatine kinase
recovery in plasma after experimental infarction in the
dog1231. Currently, this remains a controversial issue
because complete recovery of creatine kinase in plasma
has been reported after permanent coronary occlu-
sion'241, while recovery was found to be decreased after
reperfusion1251. It should be appreciated that this contro-
versy does not invalidate the conclusion of the present
study, that infarcts remain smaller after tissue plasmino-
gen activator therapy. All clinical studies suggesting an
effect of thrombolytic therapy on enzyme release have
claimed reperfusion-induced enhancement of release.
This implies that the 12% reduction of infarct size in
patients treated with tissue plasminogen activator could
only be under-estimated, and that the true benefits might
be greater.
For HBDH, complete recovery in plasma after
permanent coronary occlusion has been reported'241. In a
large clinical trial, the relationship between release of
HBDH and left ventricular ejection fraction remained
unaltered by thrombolytic therapy1261, indicating that no
reperfusion-induced extra release of HBDH occurs. The
relationship between left ventricular ejection fraction
and enzymatic infarct size was identical in patients
treated with streptokinase or direct angioplasty1271. Simi-
larly, in the present study the relationship between
HBDH infarct size and left ventricular function was
independent of the therapeutic regimen (Fig. 4). This
supports the validity of HBDH infarct size measure-
ments for comparison of different reperfusion regimens.
Effect of infarct artery patency on
infarct size
The reduction of infarct size by the tissue plasminogen
activator regimens, compared to streptokinase, could be
explained by improved 90 min patency of the infarct-
related artery. It is also interesting to note that reduction
of infarct size was not restricted to patients with early
complete perfusion (TIMI-3). Patients with partial per-
fusion (TIMI-2) also had smaller infarcts than those
with an occluded infarct related artery (TIMI-01).
Others have reported a lack of infarct size reduction in
patients with TIMI-2 flow'281. A possible explanation for
this discrepancy could be the somewhat later angiogra-
phy in the TEAM-2 study: a mean delay of 2-4 h vs 1-6 h
in the present study. This is supported by data from 72
patients in the present study who had angiography
between 2 and 4 h after initiation of thrombolytic
therapy. In these patients, infarct size was 3-41 g-eq . 1 ~',
5-29 g-eq . 1"' and 4-99 eq . 1"' for TIMI perfusion
grades, 3, 2 and 0-1 respectively (P=042), so no benefit
was apparent in patients with TIMI-2 flow between 2
and 4 h. Thus, early incomplete perfusion (TIMI-2)
might be adequate for some recovery of ischaemic
myocytes. Alternatively, some of these patients may
have further clot resolution with complete perfusion
(TIMI-3) before necrosis has been completed.
Effect of infarct artery patency on
acceleration of enzyme release
Earlier release of myocardial enzymes into plasma was
already noted in the first study on thrombolysis after
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acute myocardial infarction'291 and was thought to re-
flect enhanced washout of enzymes due to thrombolysis-
induced restoration of blood flow or possible
reperfusion injury1301. Since then, large trials have
confirmed that reperfusion does accelerate myocardial
enzyme release131-321. The difference in enzyme release
pattern between patients treated with tissue plasminogen
activator vs streptokinase in the present study is
strikingly similar to, although smaller than, the differ-
ence between tissue plasminogen activator and placebo
in an earlier study as shown in Fig. 3. This supports the
notion that both the benefit of accelerated tissue plas-
minogen activator vs streptokinase and the larger benefit
of tissue plasminogen activator vs placebo are caused by
more rapid coronary reperfusion by accelerated tissue
plasminogen activator.
The more rapid evolution of infarction during
thrombolytic therapy has been confirmed independently
by serial ECG analysis in a trial by the European
Cooperative Study Group1331. In that trial, limitation of
infarct size was apparent since patients receiving tissue
plasminogen activator had fewer Q waves after 10-20
days than the placebo group. However, at 6 h after
initiation of therapy, Q waves were more pronounced
although the ST-segment had resolved more rapidly in
patients allocated to thrombolytic therapy. Early release
of various myocardial marker proteins is now widely
used as a non-invasive indicator of successful reper-
fusion in individual patients, although the sensitivity and
specificity of this method are not established. In
the evaluation of thrombolytic therapy, acceleration
of enzyme release is a more sensitive parameter than
reduction of infarct size.
Limitation of infarct size and reduced
mortality
Collectively, the large placebo-controlled or open trials
of thrombolytic therapy have demonstrated a marked
reduction in mortality for patients presenting to hospital
within 6 to 12 h of the onset of symptoms'381. In trials
that studied the release of HBDH (or LDH1), reduc-
tions of infarct size between 20% and 35% were consist-
ently found'1'-12-34-351. Both reduction of mortality111 as
well as reduction of HBDH release136'371 were most
impressive in patients treated within 1 h of the first
symptoms. Similar trends were observed in the GUSTO
study, with a 14% reduction in mortality for patients
treated with tissue plasminogen activator reported in the
main trial'11 which corresponded to a 12% reduction in
infarct size as shown in this study.
To conclude: the presented data are in full agree-
ment with and support the concept that more rapid
reperfusion (by accelerated tissue plasminogen activator,
in comparison with the streptokinase regimens in
GUSTO) salvages myocytes, resulting in limitation of
infarct size, preservation of left ventricular function and
improved survival. The observed association between
limitation of infarct size and improved survival in
this and other studies'"12-351 indicates that infarct size
measurements may be applied to compare the clinical
efficacy of different therapeutic regimens in medium size
trials.
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